Il2 (DrugBank: -)
2 diseases| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 13 | 多発性硬化症／視神経脊髄炎 | 1 |
| 60 | 再生不良性貧血 | 3 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02424396 (ClinicalTrials.gov) | June 13, 2016 | 20/4/2015 | Biological Activity and Safety of Low Dose IL2 in Relapsing Remitting Multiple Sclerosis | Biological Activity and Safety of Low Dose IL2 in Relapsing Remitting Multiple Sclerosis. Multicentric Randomized Study | Relapsing Remitting Multiple Sclerosis | Drug: IL2;Drug: Placebo | Assistance Publique - Hôpitaux de Paris | Fondation ARSEP/AFM | Completed | 18 Years | 65 Years | All | 30 | Phase 2 | France |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2020-002031-29-FR (EUCTR) | 21/12/2020 | 10/07/2020 | REGN7257 in Adult Patients with Severe Aplastic Anemia That Is Refractory to or Relapsed on Immunosuppressive Therapy | A PHASE 1/2 STUDY OF REGN7257 (ANTI-INTERLEUKIN 2 RECEPTOR SUBUNIT GAMMA [IL2RG] MONOCLONAL ANTIBODY) IN PATIENTS WITH SEVERE APLASTIC ANEMIA THAT IS REFRACTORY TO OR RELAPSED ON IMMUNOSUPPRESSIVE THERAPY | SEVERE APLASTIC ANEMIA MedDRA version: 20.0;Level: LLT;Classification code 10002274;Term: Anemia aplastic;System Organ Class: 100000004851;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18] | Product Code: REGN7257 INN or Proposed INN: Not Applicable Other descriptive name: HUMAN IGG4 ISOTYPE MONOCLONAL (IL2-RG) ANTIBODY | Regeneron Pharmaceuticals, Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 48 | Phase 1;Phase 2 | United States;France;United Kingdom;Korea, Republic of | ||
| 2 | NCT04409080 (ClinicalTrials.gov) | November 30, 2020 | 26/5/2020 | REGN7257 in Adult Patients With Severe Aplastic Anemia That Is Refractory to or Relapsed on Immunosuppressive Therapy | A Phase 1/2 Study of REGN7257 (Anti-Interleukin 2 Receptor Subunit Gamma [IL2RG] Monoclonal Antibody) in Patients With Severe Aplastic Anemia That Is Refractory to or Relapsed on Immunosuppressive Therapy | Severe Aplastic Anemia (SAA) | Drug: REGN7257 | Regeneron Pharmaceuticals | NULL | Not yet recruiting | 18 Years | N/A | All | 48 | Phase 1;Phase 2 | NULL |
| 3 | EUCTR2020-002031-29-GB (EUCTR) | 05/11/2020 | 30/06/2020 | REGN7257 in Adult Patients with Severe Aplastic Anemia That Is Refractory to or Relapsed on Immunosuppressive Therapy | A PHASE 1/2 STUDY OF REGN7257 (ANTI-INTERLEUKIN 2 RECEPTOR SUBUNIT GAMMA [IL2RG] MONOCLONAL ANTIBODY) IN PATIENTS WITH SEVERE APLASTIC ANEMIA THAT IS REFRACTORY TO OR RELAPSED ON IMMUNOSUPPRESSIVE THERAPY | SEVERE APLASTIC ANEMIA MedDRA version: 20.0;Level: LLT;Classification code 10002274;Term: Anemia aplastic;System Organ Class: 100000004851;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18] | Product Code: REGN7257 INN or Proposed INN: Not Applicable Other descriptive name: HUMAN IGG4 ISOTYPE MONOCLONAL (IL2-RG) ANTIBODY | Regeneron Pharmaceuticals, Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 48 | Phase 1;Phase 2 | United States;France;United Kingdom;Korea, Republic of |